A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Great cash flow. Almost no debt. Double digit royalties coming in this year in addition to potential cash payment $35mil from Merck. I'm riding this one out to $7/share
35% drop in one day. Fundamentals of the company have not changed. I look at this as an excellent buy opportunity and doubled my position.